Comparative study of therapeutic effect of dibenyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia

Urologia Internationalis

Volumn 60, Issue 2, 1998, Pages 85-91

  Kuo, Hann Chorng ^a  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Benign prostatic hyperplasia; Dibenyline; Finasteride; Prostatism, severe

Indexed keywords

FINASTERIDE; PHENOXYBENZAMINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMMUNITY HOSPITAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ECHOGRAPHY; FOLLOW UP; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATISM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SYMPTOM; URINE FLOW RATE; UROFLOWMETRY; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; MALE; PHENOXYBENZAMINE; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME; URINARY RETENTION; URODYNAMICS;

EID: 0031891816     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030217     Document Type: Article

References (26)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479.
2. Nielsen KK, Nordling J, Hald T: Critical review of the diagnosis of prostalic obstruction. Neurourol Urodyn 1994;13:201-217.
3. Eri LM, Treter KJ: Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995;154:923-934.
4. Andersen JT, Ekman P, Wolf H, Beistand HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K, Scandinavian BPH Study Group: Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995;46:631-637.
5. Stoner E. Finasteride Study Group: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994,43:284-294.
6. Moore E, Bracken B, Bremner W, Geller J, Imperato-McGinley J, McConnell J, Roy J, Tenover L, Vaughan D, Pappas F, Cook T, Gormley G, Stoner E: Proscar, Five-year experience. Eur Urol 1995,28:304-309.
7. Caine M, Pfau A, Perlberg S: The use of alphaadrenergic blockers m benign prostatic obstruction. Br J Urol 1976;48:255-263.
8. Kreder KJ: Combination drug therapy for benign prostatic hyperplasia. JAMA 1995;274:359.
9. Recommendation of the International Consensus Committee 1991; in Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, Murphy GM (eds): Proceedings of the International Consultation on Benign Prostatic Hyperplasia (BPH), Paris, 1991, pp 279-288.
10. Barry MJ, Williford WO, Chang Y, et al: Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-1774.
11. Greene DR, Egawa S, Hellerstein DK, Scardino PT: Sonographic measurements of transition zone of prostate in men with and without benign prostatic hyperplasia. Urology 1990;36:293-299.
12. Kuo HC, Chang SC, Hsu T: Predictive factors for successful surgical outcome of benign prostatic hypertrophy. Eur Urol 1993;24:12-19.
13. Drach GW, Layton TN, Binard WJ: Male peak urinary flow rate: Relationship to volume voided and age. J Urol 1979;122:210-214.
14. Oesterling JE: Benign prostatic hyperplasia: Overview 1996. Curr Opin Urol 1996;6:1.
15. Malenka DJ, Roos N, Fisher ES, Mclerran D, Whaley FS, Barry MJ, Bruskewitz R, Wennberg JE: Further study of the increased mortality following transurethral prostatectomy: A chart-based analysis. J Urol 1990;144:224-228.
16. Abrams PH, Shah PJR, Stone R, Choa RG: Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 1982;54:527-530.
17. Lepor H, Auerbach S, Puras-Baez A, et al: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992;148:1467-1474.
18. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Norma Dias, Multicenter Study Group: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J Urol 1995;154:105-109.
19. Abrams P, Schulman CC, Vaage S, European Tamsulosin Study Group: Tamsulosin, a selective alpha-1c adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol 1995;76:325-336.
20. Tammela TLJ, Kontturi MJ: Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outlet obstruction due to benign prostatic hyperplasia. J Urol 1995;154:1466-1469.
21. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormiley G, Haakenson C, Machi M, Narayan P, Padley RJ: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-539.
22. Kuo HC, Tsai TC: Assessment of prostatic obstruction and bladder function by urodynamic pressure flow study. J Formosan Med Assoc 1987;86:1084-1092.
23. Venrooij GEPM, Boon TA, Gier RPE: International prostate symptom score and quality of life assessment versus urodynamic parameters in men with benign prostatic hyperplasia symptoms. J Urol 1995;153:1516-1519.
24. Barry MJ, Fowler FJ Jr, Oleary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK, Measurement Committee of the American Urological Association: The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549.
25. Riehmann M, Jonler M: Controversies about the clinical assessment of benign prostatic hyperplasia. Scand J Urol Nephrol 1995;(suppl 172):81-94.
26. Garraway WM, Armstrong C, Auld S, King D, Simpson RJ: Follow-up of a cohort of men with untreated benign prostatic hyperplasia. Eur Urol 1993;24:313-318.